Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Wei Li
AddedMar 31, 2024
UpdatedMay 1, 2026
Wei Li

Wei Li

Board Member, Innovent Biologics

Wei Li's Career

Innovent Biologics
Innovent Biologics

Suzhou, Jiangsu, CN

Board Member· Board
Kymera Therapeutics
Kymera Therapeutics

Watertown, MA, US

Board Member· Board
Medeor Therapeutics
Medeor Therapeutics

San Mateo, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Wei Li's Career

Innovent Biologics
Innovent Biologics
Public$3B5.6k2011Suzhou, Jiangsu, CN
Board Member· Board

Leadership at Innovent Biologics

Michael YuMichael YuBoard Member
Yu DechaoYu DechaoBoard Member
Prof Dr Charles Leland Cooney PhDProf Dr Charles Leland Cooney PhDBoard Member
Nick ChenNick ChenBoard Member
Joyce I-Yin HsuJoyce I-Yin HsuBoard Member
Michael De-ChaoMichael De-ChaoCEO

Similar to Innovent Biologics

WuXi BiologicsWuXi BiologicsWuxi, Anhui, CNBiologics, Drug Developmentest. 2014WuXi BiologicsWuxi, Anhui, CN · est. 2014

WuXi Biologics: A global CRDMO providing integrated platforms for biologics drug development.

Public6.3k
Livzon MabpharmLivzon MabpharmZhuhai, Guangdong, CNAntibody Drugs, Pharmaceuticalsest. 2010Livzon MabpharmZhuhai, Guangdong, CN · est. 2010

China-based pharmaceutical company specializing in research, development, production, and sales of pharmaceutical products.

Public8.3k
MacroGenicsMacroGenicsRockville, MD, USest. 2000MacroGenicsRockville, MD, US · est. 2000

US-based MacroGenics, Inc. develops novel biologics for cancer, autoimmune disorders, and infectious diseases.

Public · $165.9M357
Sino BiopharmaceuticalSino BiopharmaceuticalVictoria, Central and Western District, HKMedicine, Pharmaceuticalsest. 2000Sino BiopharmaceuticalVictoria, Central and Western District, HK · est. 2000

Sino Biopharmaceutical Ltd., a Chinese company specializing in the development and sale of medical treatments for ophthalmia and hepatitis.

Public25.6k
Kymera Therapeutics
Kymera Therapeutics
Public$879M1672017Watertown, MA, US
Board Member· Board

Leadership at Kymera Therapeutics

Donald NicholsonDonald NicholsonBoard Member
Andrew HedinAndrew HedinBoard Member
Bruce BoothBruce BoothBoard Member
Nello MainolfiNello MainolfiCo-Founder
Joanna HorobinJoanna HorobinBoard Member
Jeff AlbersJeff AlbersBoard Member
Medeor Therapeutics
Medeor Therapeutics
Series B$75.8M102012San Mateo, CA, US
Board Member· Board

Leadership at Medeor Therapeutics

Steven DeitcherSteven DeitcherBoard Member
Frank KungFrank KungBoard Member
Giovanni FerraraGiovanni FerraraCEO
Cp LiuCp LiuBoard Member
Peter KolchinskyPeter KolchinskyBoard Member
Anand MehraAnand MehraBoard Member

Similar to Medeor Therapeutics

Tract TherapeuticsTract TherapeuticsChicago, IL, USMedicalest. 2013Tract TherapeuticsChicago, IL, US · est. 2013

Nova Biomedical: Innovating immune balance restoration for solid organ transplant patients.

Series B · $15M5
LTZ TherapeuticsLTZ TherapeuticsSan Francisco, CA, USImmunotherapy, Therapeuticsest. 2022LTZ TherapeuticsSan Francisco, CA, US · est. 2022

LTZ: Innovating immunotherapies for cancer and diseases with unmet clinical needs.

Seed · $27M16
Meditope BiosciencesMeditope BiosciencesPasadena, CA, USCancer Therapeuticsest. 2011Meditope BiosciencesPasadena, CA, US · est. 2011

Meditope Biosciences: Biotech firm specializing in antibody-based cancer treatments.

Series A · $3.6M6
SpheringenicsSpheringenicsAtlanta, GA, USCell Therapiesest. 2007SpheringenicsAtlanta, GA, US · est. 2007

SpherIngenics: Leading biotech firm specializing in innovative cell-based medicinal therapies.

Pre-Seed · $730k4

People Similar to Wei Li

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao